VistaGen Therapeutics
Biopharmaceutical company developing innovative product candidates for patients with diseases and disorders involving the cns.
Launch date
Employees
Market cap
€78.5m
Enterprise valuation
(€18m) (Public information from Sep 2024)
Share price
$3 VTGN
San Francisco California (HQ)
Authorizing premium user...